Brief Report: Comparison of Continuous Glucose Monitoring and Finger-Prick Blood Glucose Levels in Hospitalized Patients Administered Basal-Bolus Insulin

2013 ◽  
Vol 15 (3) ◽  
pp. 241-245 ◽  
Author(s):  
Morton G. Burt ◽  
Gregory W. Roberts ◽  
Norma R. Aguilar-Loza ◽  
Stephen N. Stranks
Keyword(s):  
Blood Glucose ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Hospitalized Patients ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Finger Prick ◽  
Bolus Insulin ◽  
Basal Bolus

scholarly journals Correlation between short- and mid-term hemoglobin A1c and glycemic control determined by continuous glucose monitoring

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Jen-Hung Huang ◽  
Yung-Kuo Lin ◽  
Ting-Wei Lee ◽  
Han-Wen Liu ◽  
Yu-Mei Chien ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glycemic Control ◽  
Continuous Glucose Monitoring ◽  
Hemoglobin A1c ◽  
Glucose Monitoring ◽  
Mean Amplitude ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Before And After ◽  
Patients With Diabetes

Abstract Background Glucose monitoring is vital for glycemic control in patients with diabetes mellitus (DM). Continuous glucose monitoring (CGM) measures whole-day glucose levels. Hemoglobin A1c (HbA1c) is a vital outcome predictor in patients with DM. Methods This study investigated the relationship between HbA1c and CGM, which remained unclear hitherto. Data of patients with DM (n = 91) who received CGM and HbA1c testing (1–3 months before and after CGM) were retrospectively analyzed. Diurnal and nocturnal glucose, highest CGM data (10%, 25%, and 50%), mean amplitude of glycemic excursions (MAGE), percent coefficient of variation (%CV), and continuous overlapping net glycemic action were compared with HbA1c values before and after CGM. Results The CGM results were significantly correlated with HbA1c values measured 1 (r = 0.69) and 2 (r = 0.39) months after CGM and 1 month (r = 0.35) before CGM. However, glucose levels recorded in CGM did not correlate with the HbA1c values 3 months after and 2–3 months before CGM. MAGE and %CV were strongly correlated with HbA1c values 1 and 2 months after CGM, respectively. Diurnal blood glucose levels were significantly correlated with HbA1c values 1–2 months before and 1 month after CGM. The nocturnal blood glucose levels were significantly correlated with HbA1c values 1–3 months before and 1–2 months after CGM. Conclusions CGM can predict HbA1c values within 1 month after CGM in patients with DM.

Advantages and Disadvantages of Realtime Continuous Glucose Monitoring in People with Type 2 Diabetes

2012 ◽  
Vol 08 (01) ◽  
pp. 22 ◽  
Author(s):  
M Susan Walker ◽  
Stephanie J Fonda ◽  
Sara Salkind ◽  
Robert A Vigersky ◽  
◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Glucose Levels ◽  
Advantages And Disadvantages ◽  
Blood Glucose Levels

Previous research has shown that realtime continuous glucose monitoring (RT-CGM) is a useful clinical and lifestyle aid for people with type 1 diabetes. However, its usefulness and efficacy for people with type 2 diabetes is less known and potentially controversial, given the continuing controversy over the efficacy of self-monitoring of blood glucose (SMBG) in this cohort. This article reviews theextantliterature on RT-CGM for people with type 2 diabetes, and enumerates several of the advantages and disadvantages of this technology from the perspective of providers and patients. Even patients with type 2 diabetes who are not using insulin and/or are relatively well controlled on oral medications have been shown to spend a significant amount of time each day in hyperglycemia. Additional tools beyond SMBG are necessary to enable providers and patients to clearly grasp and manage the frequency and amplitude of glucose excursions in people with type 2 diabetes who are not on insulin. While SMBG is useful for measuring blood glucose levels, patients do not regularly check and SMBG does not enable many to adequately manage blood glucose levels or capture marked and sustained hyperglycemic excursions. RT-CGM systems, valuable diabetes management tools for people with type 1 diabetes or insulin-treated type 2 diabetes, have recently been used in type 2 diabetes patients. Theextantstudies, although few, have demonstrated that the use of RT-CGM has empowered people with type 2 diabetes to improve their glycemic control by making and sustaining healthy lifestyle choices.

scholarly journals Correlation Between Short- and Mid-Term Hemoglobin A1c and Glycemic Control Determined by Continuous Glucose Monitoring

2021 ◽  
Author(s):  
Jen-Hung Huang ◽  
Yung-Kuo Lin ◽  
Ting-Wei Lee ◽  
Han-Wen Liu ◽  
Yu-Mei Chien ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glycemic Control ◽  
Continuous Glucose Monitoring ◽  
Hemoglobin A1c ◽  
Glucose Monitoring ◽  
Mean Amplitude ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Before And After ◽  
Patients With Diabetes

Abstract Background: Glucose monitoring is vital for glycemic control in patients with diabetes mellitus (DM). Continuous glucose monitoring (CGM) measures whole-day glucose levels. Hemoglobin A1c (HbA1c) is a vital outcome predictor in patients with DM. Methods: This study investigated the relationship between HbA1c and CGM, which remained unclear hitherto. Data of patients with DM (n = 91) who received CGM and HbA1c testing (1-3 months before and after CGM) were retrospectively analyzed. Diurnal and nocturnal glucose, highest CGM data (10%, 25%, and 50%), mean amplitude of glycemic excursions (MAGE), percent coefficient of variation (%CV), and continuous overlapping net glycemic action were compared with HbA1c values before and after CGM. Results: The CGM results were significantly correlated with HbA1c values measured 1 (r = 0.69) and 2 (r = 0.39) months after CGM and 1 month (r = 0.35) before CGM. However, glucose levels recorded in CGM did not correlate with the HbA1c values 3 months after and 2-3 months before CGM. MAGE and %CV were strongly correlated with HbA1c values 1 and 2 months after CGM, respectively. Diurnal blood glucose levels were significantly correlated with HbA1c values 1-2 months before and 1 month after CGM. The nocturnal blood glucose levels were significantly correlated with HbA1c values 1-3 months before and 1-2 months after CGM.Conclusions: CGM can predict HbA1c values within 1 month after CGM in patients with DM.

scholarly journals Continuous glucose monitoring in obese pregnant women with no hyperglycemia on glucose tolerance test

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0253047
Author(s):  
Rosa Maria Rahmi ◽  
Priscila de Oliveira ◽  
Luciano Selistre ◽  
Paulo Cury Rezende ◽  
Gabriela Neuvald Pezzella ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glucose Tolerance ◽  
Pregnant Women ◽  
Continuous Glucose Monitoring ◽  
Glucose Tolerance Test ◽  
Glucose Monitoring ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Glucose Levels ◽  
Blood Glucose Levels

Objective The objective of the present study was to compare 24-hour glycemic levels between obese pregnant women with normal glucose tolerance and non-obese pregnant women. Methods In the present observational, longitudinal study, continuous glucose monitoring was performed in obese pregnant women with normal oral glucose tolerance test with 75 g of glucose between the 24th and the 28th gestational weeks. The control group (CG) consisted of pregnant women with normal weight who were selected by matching the maternal age and parity with the same characteristics of the obese group (OG). Glucose measurements were obtained during 72 hours. Results Both the groups were balanced in terms of baseline characteristics (age: 33.5 [28.7–36.0] vs. 32.0 [26.0–34.5] years, p = 0.5 and length of pregnancy: 25.0 [24.0–25.0] vs. 25.5 [24.0–28.0] weeks, p = 0.6 in the CG and in the OG, respectively). Pre-breakfast glycemic levels were 77.77 ± 10.55 mg/dL in the CG and 82.02 ± 11.06 mg/dL in the OG (p<0.01). Glycemic levels at 2 hours after breakfast were 87.31 ± 13.10 mg/dL in the CG and 93.48 ± 18.74 mg/dL in the OG (p<0.001). Daytime blood glucose levels were 87.6 ± 15.4 vs. 93.1 ± 18.3 mg/dL (p<0.001) and nighttime blood glucose levels were 79.3 ± 15.8 vs. 84.7 ± 16.3 mg/dL (p<0.001) in the CG and in the OG, respectively. The 24-hour, daytime, and nighttime values of the area under the curve were higher in the OG when compared with the CG (85.1 ± 0.16 vs. 87.9 ± 0.12, 65.6 ± 0.14 vs. 67.5 ± 0.10, 19.5 ± 0.07 vs. 20.4 ± 0.05, respectively; p<0.001). Conclusion The results of the present study showed that obesity in pregnancy was associated with higher glycemic levels even in the presence of normal findings on glucose tolerance test.

scholarly journals Fluctuation of blood glucose levels in an infant with an ileostomy on continuous glucose monitoring: A case report

2018 ◽  
Vol 27 (1) ◽  
pp. 39-43
Author(s):  
Seiichi Tomotaki ◽  
Tetsuo Naramura ◽  
Junko Hanakawa ◽  
Katsuaki Toyoshima ◽  
Koji Muroya ◽  
...  
Keyword(s):  
Case Report ◽  
Blood Glucose ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Glucose Levels ◽  
Blood Glucose Levels

scholarly journals An Integrative Literature Review of Basal-Bolus Insulin versus Sliding-Scale Insulin for Glycemic Management in the Hospitalized Non-Critically Ill Type 2 Diabetic Patient

2018 ◽  
Vol 16 (12) ◽  
pp. 909-919
Author(s):  
Lindy HERR ◽  
Ladda THIAMWONG
Keyword(s):  
Blood Glucose ◽  
Literature Review ◽  
Critically Ill ◽  
Patient Outcomes ◽  
Insulin Regimen ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Sliding Scale ◽  
Bolus Insulin ◽  
Basal Bolus

Diabetes is an increasingly common chronic disease that affects the body’s normal ability to control blood glucose levels due to impaired use of the hormone insulin. It is estimated that one out of every 4 adults who are hospitalized also have a diagnosis of diabetes. Diabetic inpatients face unique challenges in regards to managing their blood glucose while hospitalized due to the physiological stress of acute illness. Unfortunately, those who experience inadequate blood glucose management in the hospital are at an increased risk for poor patient outcomes, such as infection, increased length of stay, and death. There are multiple medications used to regulate blood sugar levels; however, the most commonly prescribed treatment for inpatients is the traditional sliding-scale regimen followed by the basal-bolus insulin regimen. An integrated literature review was conducted to determine if basal-bolus insulin is more effective than sliding-scale insulin in managing blood glucose levels of non-critically ill diabetic inpatients. Four well-known databases were searched and 5 relevant quantitative research articles were obtained and analyzed. The majority of the evidence supports basal-bolus insulin as the most effective treatment for managing blood glucose and preventing hyperglycemia without increasing the risk for hypoglycemia. Health care providers should order basal-bolus insulin accordingly in order to improve patient outcomes. Future research that questions why sliding-scale insulin is still widely prescribed may identify barriers related to ordering basal-bolus insulin and assist in decreasing related adverse events.

Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report

2020 ◽  
Vol 33 (7) ◽  
pp. 951-955 ◽  
Author(s):  
Toby Candler ◽  
David McGregor ◽  
Kruthika Narayan ◽  
Chris Moudiotis ◽  
Christine P. Burren
Keyword(s):  
Insulin Resistance ◽  
Blood Glucose ◽  
Treatment Options ◽  
Prader Willi Syndrome ◽  
Feeding Difficulties ◽  
Glucose Levels ◽  
Insulin Requirements ◽  
Bolus Insulin ◽  
Basal Bolus

AbstractObjectivesPrader-Willi Syndrome (PWS) is characterised by hyperphagia often leading to obesity; a known risk factor for insulin resistance and type 2 (T2) diabetes. We present a prepubertal girl with PWS who developed diabetes.Case presentationOur case was diagnosed with PWS in infancy following investigation for profound central hypotonia and feeding difficulties. She commenced growth hormone (GH) aged 8 years for short stature and treatment improved linear growth. At age 12 years, she presented with polydipsia, polyuria and vulvovaginitis. She was overweight (BMI SDS +1.43). Diabetes was diagnosed (Blood glucose = 24.2 mmol/L, HbA1c = 121 mmol/mol or 13.2%). She was not acidotic and had negative blood ketones. Autoantibodies typical of type 1 diabetes were negative. She was initially treated with basal bolus insulin regime. GH was discontinued 3 months later due to concerns regarding GH-induced insulin resistance. Off GH, insulin requirements reduced to zero, allowing Metformin monotherapy. However off GH, she reported significant lethargy with static growth and increased weight. Combinations of Metformin with differing insulin regimes did not improve glucose levels. Liraglutide (GLP-1 agonist) and Metformin did not improve glucose levels nor her weight. Liraglutide and Empaglifozin (SGLT-2 inhibitor) therapy used in combination were well tolerated and demonstrated rapid normalisation of blood glucose and improvement in her HbA1c to within target (48 mmol/mol) which was sustained after 6 months of treatment.ConclusionsNewer treatments for type 2 diabetes (e. g. GLP-1 agonists or SGLT-2 inhibitors) offer potential treatment options for those with diabetes and PWS when conventional treatments are ineffective.

scholarly journals A Review of Non-Invasive Optical Systems for Continuous Blood Glucose Monitoring

Sensors ◽  
2021 ◽  
Vol 21 (20) ◽  
pp. 6820
Author(s):  
Bushra Alsunaidi ◽  
Murad Althobaiti ◽  
Mahbubunnabi Tamal ◽  
Waleed Albaker ◽  
Ibraheem Al-Naib
Keyword(s):  
Blood Glucose ◽  
Glucose Monitoring ◽  
Daily Basis ◽  
Glucose Sensing ◽  
Blood Glucose Monitoring ◽  
Optical Systems ◽  
Glucose Levels ◽  
Non Invasive ◽  
Blood Glucose Levels ◽  
Continuous Blood Glucose Monitoring

The prevalence of diabetes is increasing globally. More than 690 million cases of diabetes are expected worldwide by 2045. Continuous blood glucose monitoring is essential to control the disease and avoid long-term complications. Diabetics suffer on a daily basis with the traditional glucose monitors currently in use, which are invasive, painful, and cost-intensive. Therefore, the demand for non-invasive, painless, economical, and reliable approaches to monitor glucose levels is increasing. Since the last decades, many glucose sensing technologies have been developed. Researchers and scientists have been working on the enhancement of these technologies to achieve better results. This paper provides an updated review of some of the pioneering non-invasive optical techniques for monitoring blood glucose levels that have been proposed in the last six years, including a summary of state-of-the-art error analysis and validation techniques.

Sign in / Sign up

Export Citation Format

Share Document